Mexico just made ANVISA approval worth more internationally
ANVISA announced four days ago that Mexico’s COFEPRIS now recognizes ANVISA’s drug approval decisions as equivalent, creating a fast-track registration pathway. For any company with an active ANVISA authorization, this changes the calculus on which Latin American market to enter next, and in what order.
What actually changed, in one paragraph
Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) will now treat requirements, tests, and evaluation procedures already conducted by ANVISA as equivalent to its own. A drug already evaluated and approved by ANVISA can pursue Mexican sanitary registration through a faster process, provided the product is essentially identical to what Brazil authorized and that authorization is still active.
Already approved in Brazil? This changes your Mexico timeline
If your product holds active ANVISA authorization, this new pathway may significantly shorten your route into the Mexican market. Get a direct read on whether your specific product qualifies.
→ Book a Paid Consulting Session (WhatsApp)The numbers that matter
Which products qualify
| Product category | Covered? |
|---|---|
| New molecule drugs | Yes |
| Generic drugs | Yes |
| Innovative biotechnology drugs | Yes |
| Biocomparable (biosimilar) products | Yes |
| Biological products and vaccines | Yes |
To use the pathway, the product presented in Mexico must have characteristics essentially identical to what ANVISA authorized, and the Brazilian authorization must remain active (source). The required legal, technical, and scientific documentation must still be submitted directly to COFEPRIS.
This is not automatic approval, it’s avoided duplication
ANVISA’s announcement is specific: when the required documentation is complete and properly filed, COFEPRIS will not re-conduct technical scrutiny on aspects ANVISA already evaluated. It does not mean Mexican registration happens without a filing, and it explicitly preserves COFEPRIS’s full autonomy over the final decision made in Mexico.
Why ANVISA is calling this a milestone
ANVISA’s director-president, Leandro Safatle, described Mexico’s decision as unprecedented: “O México tomou a decisão de aceitar os registros da Anvisa, algo inédito até então” (Mexico made the decision to accept ANVISA’s registrations, something unprecedented until now), calling it one of the biggest advances in Brazilian health diplomacy (source). Safatle also framed the timeline shift directly: a process that could previously take years may now conclude in up to 45 business days, while maintaining quality, safety, and efficacy guarantees.
What this means for market sequencing strategy
This development directly updates the calculus for brands weighing Brazil against Mexico for Latin America entry. A brand that secures ANVISA approval first now has a credible, faster secondary pathway into Mexico, rather than starting Mexico’s process from zero. ANVISA’s leadership explicitly framed this as a precedent for expanding similar cooperation with other regional authorities going forward.
Planning ANVISA approval with Mexico as your next market?
This agreement can meaningfully change your Brazil-to-Mexico sequencing and timeline. Get a specific read on how it applies to your product.
→ Book a Paid Consulting Session (WhatsApp) → Email: wagner@farmacerto.comRelated Reading
Brazil vs. Mexico vs. Colombia: Where to Enter First The Full Brazil Market Entry Guide Why 65% of New Supplements Get Rejected by ANVISAFrequently Asked Questions
References: ANVISA, official notice, “México reconhece decisões regulatórias da Anvisa e cria procedimento simplificado para registro de medicamentos,” published September 3, 2026, gov.br/anvisa. Statement of Leandro Safatle, Director-President of ANVISA, in the same official notice.
Descubra mais sobre FarmaCerto
Assine para receber nossas notícias mais recentes por e-mail.